RODRIGUEZ RAUL R 4

What Happened Raul R. Rodriguez, CEO, President and Director of Rigel Pharmaceuticals (RIGL), was granted 53,915 restricted stock units (RSUs) on February 17, 2026. The award is reported at $0.00 per share (total reported value $0) because these are compensation RSUs that convert to shares only upon vesting. This is an equity award (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-17; Form 4 filed: 2026-02-19 (appears timely under the 2-business-day filing rule).
• Grant amount and price: 53,915 RSUs at $0.00 reported.
• Shares owned after transaction: Not specified in this Form 4.
• Footnote: The RSUs vest quarterly over three years; the first quarterly vesting date is March 31, 2026.
• No 10b5-1 plan, tax-withholding sale, or immediate sale reported in this filing.

Context RSUs are a form of compensation that convert to actual shares only as they vest; they do not represent an immediate cash purchase or sale. Such awards are common for executive pay and do not by themselves indicate a buy/sell signal — they increase potential future ownership if and when they vest.